Pharsight

Movantik patents expiration

MOVANTIK's oppositions filed in EPO
MOVANTIK Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7662365 REDHILL Polymer conjugates of opioid antagonists
Oct, 2022

(11 months ago)

US7786133 REDHILL Chemically modified small molecules
Sep, 2028

(4 years from now)

US9012469 REDHILL Crystalline naloxol-peg conjugate
Apr, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617530 REDHILL Polymer conjugates of opioid antagonists
Oct, 2022

(11 months ago)

US7056500 REDHILL Polymer conjugates of opioid antagonists
Jun, 2024

(8 months from now)

US8067431 REDHILL Chemically modified small molecules
Dec, 2024

(1 year, 2 months from now)

Movantik is owned by Redhill.

Movantik contains Naloxegol Oxalate.

Movantik has a total of 6 drug patents out of which 2 drug patents have expired.

Expired drug patents of Movantik are:

  • US8617530
  • US7662365

Movantik was authorised for market use on 16 September, 2014.

Movantik is available in tablet;oral dosage forms.

Movantik can be used as treatment of opioid-induced constipation.

The generics of Movantik are possible to be released after 02 April, 2032.

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage

MOVANTIK family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic